Physician profile
Jayson W Fields
NPI 1376603654
$1,984.69
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $50.59 · 2022: $225 · 2023: $675 · 2024: $858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,534.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,533.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $310.33 | 2022-2024 | |
| Lilly USA, LLC | $256.11 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $231.26 | 2022-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $212.31 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $154.48 | 2022-2024 | |
| Actelion Pharmaceuticals US, INC. | $125.00 | 2019 | |
| Astellas Pharma US INC | $97.12 | 2023-2024 | Veozah, Myrbetriq |
| Shield Therapeutics INC | $83.89 | 2023-2024 | Accrufer |
| Amgen INC. | $66.17 | 2019-2024 | Otezla, Repatha, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $63.70 | 2023 | |
| Abbott Laboratories | $49.35 | 2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.72 | 2022-2024 | Ofev |
| Janssen Pharmaceuticals, INC | $35.91 | 2019-2020 | |
| Radius Health, INC. | $33.69 | 2024 | Tymlos |
| Merck Sharp & Dohme LLC | $31.90 | 2020-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $30.01 | 2023 | |
| Optinose US, INC. | $29.40 | 2024 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $26.27 | 2022 | |
| Ethicon US, LLC | $24.76 | 2019 | |
| Xeris Pharmaceuticals, INC. | $18.03 | 2024 | Gvoke Hypopen |
| Neos Therapeutics, Lp | $16.62 | 2024 | Adzenys Xr-Odt |
| Idorsia Pharmaceuticals US INC | $15.40 | 2023 | Quviviq |
| Astrazeneca Pharmaceuticals Lp | $12.53 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $11.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayson Fields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.